Table 3.

Multivariable a priori (including pulmonary function tests) regressions on overall survival (OS), lung cancer-specific survival (LCS), non-lung cancer survival (NCS) in the subset cohort.

Variable	OS		LCS		NCS
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
NLR
≤ 4.0	1.0		1.0		1.0
> 4.0	1.51 (1.07–2.14)	0.02*	1.22 (0.77–1.93)	0.39	2.18 (1.24–3.84)	0.01*
Age	1.05 (1.03–1.07)	<0.0001*	1.05 (1.02–1.08)	0.0008*	1.05 (1.01–1.10)	0.03*
Gender
Male	1.0		1.0		1.0
Female	1.22 (0.67–2.22)	0.53	1.04 (0.37–1.93)	0.94	1.55 (0.53–4.50)	0.42
Charlson Score
0	1.0		1.0		1.0
1	1.41 (0.90–2.22)	0.13	1.45 (0.83–2.55)	0.20	1.39 (0.64–3.01)	0.40
2+	1.65 (1.05–2.59)	0.03*	1.40 (0.77–2.53)	0.27	2.30 (1.11–4.77)	0.03*
Race
White	1.0		1.0		1.0
Black	0.78 (0.49–1.24)	0.30	0.99 (0.58–1.68)	0.96	0.47 (0.20–1.12)	0.09
Smoker at Diagnosis
Yes	1.0		1.0		1.0
No	0.71 (0.50–0.99)	0.04*	0.76 (0.50–1.15)	0.19	0.63 (0.35–1.13)	0.12
Histology
Adenocarcinoma	1.0		1.0		1.0
Squamous	1.18 (0.83–1.68)	0.35	1.36 (0.85–2.15)	0.20	0.96 (0.55–1.70)	0.90
Other/unknown	0.85 (0.47–1.52)	0.58	1.04 (0.51–2.10)	0.92	0.62 (0.20–1.92)	0.41
T stage
< 2 cm (T1a)	1.0		1.0		1.0
2-3 cm (T1b)	1.31 (0.91–1.89)	0.14	1.40 (0.88–2.23)	0.15	1.15 (0.61–2.15)	0.67
3-5 cm (T2a)	1.21 (0.80–1.81)	0.37	1.25 (0.73–2.13)	0.42	1.15 (0.58–2.26)	0.69
Total BED	1.00 (0.99–1.00)	0.26	1.00 (0.99–1.00)	0.16	1.00 (0.99–1.01)	0.96
Pretreatment FEV1
< 30%	1.0		1.0		1.0
31-50%	0.53 (0.30–0.94)	0.03*	0.63 (0.29–1.33)	0.23	0.37 (0.15–0.93)	0.04*
51-80%	0.57 (0.33–0.99)	0.04*	0.60 (0.29–1.27)	0.18	0.51 (0.22–1.20)	0.12
> 80%	0.58 (0.30–1.11)	0.10	0.62 (0.27–1.44)	0.27	0.50 (0.18–1.38)	0.18